upcoming webinar 12| Resmetirom: The first of many new treatments changing clinical care in MASh
thursday, march 20, 2025 - 16:00 cetSpeaker: Prof. Vlad Ratziu
Hosts: Prof. Manuel Castro Cabezas & Prof. Christopher Moreno |
Guest Speaker
Prof. Vlad Ratziu 
|
WEBINAR 11| CLINICAL CONSEQUENCES OF THE NEW MASLD NOMENCLATURE
JUNE 27, 2024 - 17.00 - 18.00 CEST
|
Topic: This webinar delved into crucial topics such as the prognostic relevance of MASLD classifications and the necessity of re-validating Non-Invasive Liver Tests (NILTs) under the new guidelines. We examined considerations for emerging conditions like MetALD, offering a comprehensive analysis for healthcare professionals navigating these changes.
Speaker: Prof. Maja Thiele Hosts: Prof. Manuel Castro Cabezas & Prof. Christopher Moreno |
Guest Speaker
Prof. Maja Thiele 
|
WEBINAR 10 | GETTING GRIP ON MASH AFTER LITMUS
MARCH 12, 2024 - 17.00 - 18.00 CEST
|
Topic: During this webinar, participants had the chance to explore key topics with Prof. Manuel Romero-Gómez and hosts Prof. Manuel Castro Cabezas and Prof. Rick Grobbee. They discussed the effects of disease prevalence on noninvasive diagnostic methods, the use of lifestyle changes for better patient care, and the improvement of MASH management through clinical pathways. This session gave valuable insights into healthcare, allowing participants to deepen their understanding and contribute to better patient outcomes.
Speaker: Prof. Manuel Romero-Gómez Hosts: Prof. Manuel Castro Cabezas & Prof. Rick Grobbee |
Guest Speaker
Prof. Manuel Romero-Gomez 
|
WEBINAR 9 | LIFESTYLE INTERVENTIONS IN NAFLD/NASH
SEPTEMBER 19, 2023 - 17.00 - 18.00 CEST
|
Topic: We had the honor of hosting Prof. Shira Zelber-Sagi as our guest speaker, where she delivered an informative presentation titled "Lifestyle Interventions in NAFLD/NASH." During her presentation, Prof. Zelber-Sagi explored the relationship between diet and NAFLD, emphasizing that diet not only caused NAFLD but could also serve as an effective treatment. She discussed the importance of lifestyle changes in managing NAFLD, even small ones, and how dietary composition modification was crucial beyond weight reduction. Additionally, Professor Zelber-Sagi shared various effective ways for weight reduction and highlighted the role of physical activity in improving outcomes beyond steatosis. This was a session that promised to be both informative and practical, offering insights and strategies for managing and treating NAFLD and NASH through lifestyle interventions.
Speaker: Prof. Shira Zelber-Sagi Host: Prof. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Prof. Shira Zelber-Sagi 
|
WEBINAR 8 | WHY NASH TRIALS FREQUENTLY FAIL AND HOW TO IMPROVE THEM
MAY 23, 2023 - 17.00 - 18.00 CEST
|
Topic: Our esteemed scientific officer, Manuel Castro Cabezas, served as the guest speaker, sharing his expertise on the critical topic of "Why NASH trials frequently fail and how to improve them." With the increasing prevalence of NASH and the challenges involved in developing effective treatments, this discussion held immense significance for clinicians, researchers, and other stakeholders in the field. Participants eagerly anticipated Manuel's insights and recommendations for enhancing the success of NASH clinical trials in the future.
Speaker: Prof. Dr. Manuel Castro Cabezas Host: Prof. Dr. Diederick E. (Rick) Grobbee |
Guest Speaker
Prof. Dr. Manuel Castro Cabezas 
|
WEBINAR 7 | NOVEL DEVELOPMENTS IN THE GUT-PANCREAS-LIVER AXIS FOR NASH TREATMENT
February 21, 2023 - 17.00 - 18.00 CET
|
Topic: During this webinar, Amalia talked about the impact of GLP-1 and insulin secretion and clearance ho hepatic metabolism (and NASH). Amalia also discussed the new twincretins and their effects on hepatic fat, lipid and glucose metabolism (that are also mediated by the pancreatic hormones insulin and glucagon).
Speaker: Amalia Gastaldelli Host: Prof. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Amalia Gastaldelli 
|
WEBINAR 6 | Insulin resistance in nafld
November 29, 2022 - 17.00 - 18.00 CET
|
Topic: This webinar will focus on the close multilevel links between insulin resistance/T2DM and NAFLD:
Speaker: Dr. Onno Holleboom Host: Prof. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Dr. Onno Holeboom 
|
WEBINAR 5 | Genetic architecture of NAFLD: where do we stand?
september 27, 2022 - 17.00 - 18.00 CEST
|
Topic: Genome-wide association studies have uncovered robust and reproducible associations between several genetic variations and the natural history of NAFLD. During this webinar, Professor Eric Trépo reviewed these findings that have provided compelling new insights into the biology of NAFLD and highlighted potentially attractive pharmaceutical targets. Professor Eric Trépo also discussed potential applications and limitations of genetic variations for risk prediction in this disease.
Speaker: Prof. Eric Trépo Host: Prof. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Prof. Eric Trépo 
|
WEBINAR 4 | PUBLIC HEALTH AND POLICY RESPONSES TO NAFLD/NASH
JUNE 14, 2022 - 17.00 - 18.00 CESTTopic: This webinar by professor Lazarus focused on the impact of NAFLD and NASH and what is currently being done to tackle this disease nationally and globally. During his talk, the speaker identified what still needs to be done in the fight against NAFLD/NASH and how countries can advance the battle against this “silent” condition.
Speaker: Prof. Dr. Jeffrey Lazarus Host: Prof. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Prof. Jeffrey Lazarus 
|
WEBINAR 3 | Non-invasive diagnosis and disease staging of nafld
MARCH 22, 2022 - 17.00 - 18.00 CET
|
Guest Speaker
Prof. Hannes Hagström 
|
WEBINAR 2 | Promising phase 2 trial results of Lanifibranor in NASH
February 1, 2022 - 17.00 - 18.00 CET
|
Topic:
In this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH and shows promising results as treatment. Speaker: Prof. Sven Francque Host: Dr. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Prof. Sven Francque 
|
|
|
WEBINAR 1 | NAFLD: Patient Identification strategies
NOVEMBER 9, 2021 - 17.00 - 18.00 CET
|
Topic:
In this webinar Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely implemented and therefore this represents an unmet clinical need. Professor Schattenberg’s paper includes recommendations to address the increasing need for comprehensive models of care for NAFLD. Speaker: Prof. Jörn Schattenberg Host: Dr. Manuel Castro Cabezas Co-host: Prof. Christophe Moreno |
Guest Speaker
Prof. Jörn Schattenberg 
|
MASH
|
These webinars are part of the MASH webinar series, each focusing on recent developments or publications on MASH. The topics and publications are selected by KOLs of MASH Clinical based on relevant ground-breaking MASH research in a high-impact journal. During these webinars we offer you the opportunity to interact with original authors and experts in the MASH field.
|
|
HOST
CO-HOST
|
